Magazine

Returning to Play: The Evolution of Cardiac Guidelines for Athletes with COVID-19

Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.

Oasis of Opportunity: Strategies for Managing Healthcare’s Data Deluge

Forward-looking providers are converting reams of data from myriad sources into innovative new ways to deliver healthcare and improve efficiencies.

Stirring the Pot: Cannabis & Cardiology—How & Why to Talk with Patients About Marijuana Use

As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.

Pop Goes the Pillbox: Will Polypharmacy Problems Limit the Adoption of SGLT2 Inhibitors?

Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?

Data Dilemma: Taming Healthcare’s Beautiful Beast

To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.

Oasis of Opportunity: Strategies for Managing Healthcare’s Data Deluge

Forward-looking providers are converting reams of data from myriad sources into innovative new ways to deliver healthcare and improve efficiencies.

Stirring the Pot: Cannabis & Cardiology—How & Why to Talk with Patients About Marijuana Use

As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.

Pop Goes the Pillbox: Will Polypharmacy Problems Limit the Adoption of SGLT2 Inhibitors?

Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?

Positive Projections: TAVR/TMVR Market Likely to Double by 2023

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist.

‘Really Not Close’: TAVR Trumps SAVR in Two Trials of Low-risk Patients

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR.

Program chair previews HRS.19 highlights

The Heart Rhythm Society's 2019 scientific sessions will be held May 8-11 in San Francisco, a venue that enabled the program committee to tap into Silicon Valley’s expertise with digital health, emerging technology and innovation. HRS.19 Program Director Christine Albert, MD, MPH, gave Cardiovascular Business a preview of meeting highlights.

Live in Las Vegas: SCAI.19 Expands Focus on Live Cases

SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.